Intellia Therapeutics, Inc. (NTLA) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Intellia Therapeutics, Inc.
Intellia Therapeutics develops CRISPR-based therapies with a distinctive focus on in vivo editing — delivering editing components directly into the body via lipid nanoparticle infusion rather than editing cells outside it. Its lead programmes target transthyretin amyloidosis, where the goal is to permanently reduce production of a harmful protein in the liver, and hereditary angioedema, where a single treatment aims to prevent recurring attacks.
How Intellia Therapeutics Makes Money
Intellia is pre-commercial, funded by its cash balance and collaboration payments. There are no product revenues; value is created by advancing programmes through clinical development toward approval. The economic appeal of the in vivo approach is scalability: an infusion administered in a standard clinical setting can reach far more patients than a therapy requiring cell collection, laboratory manufacturing, and conditioning chemotherapy.
Intellia Therapeutics Revenue & Profitability Breakdown
This chart shows how Intellia Therapeutics's revenue flows through to profit. As a financial-sector company, Intellia Therapeutics doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.
Key Financial Metrics
Intellia Therapeutics, Inc. doesn't carry a meaningful trailing P/E right now, generates $-249.8M in free cash flow, runs a debt/equity ratio of 10.09, and converts shareholder equity into profit at a -55.4% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering Intellia Therapeutics, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $23.94. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Technical Price Signals
NTLA is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
NTLA Investment Case: Bull vs Bear
NTLA's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- In vivo delivery avoids the cell extraction, manufacturing, and conditioning steps that limit cell-based gene editing to specialised centres.
- Transthyretin amyloidosis has existing approved therapies requiring lifelong dosing, so a one-time treatment has clear differentiation.
- Clinical data has shown deep and durable reduction of target proteins after a single dose, supporting the core mechanism.
- A single validated in vivo platform could be redirected at many liver-expressed disease targets.
Bear Case (Key Risks)
- Permanent edits carry irreversible risk — any unexpected long-term safety signal cannot be undone by stopping treatment.
- The company is pre-revenue with substantial ongoing burn, creating recurring financing and dilution risk.
- Competing therapies for transthyretin amyloidosis, including RNA-based drugs from large companies, are already established with commercial infrastructure.
- Late-stage trials in these indications require long follow-up, delaying definitive answers on durability and safety.
What to Watch: NTLA Key Metrics
NTLA Stock — Frequently Asked Questions
Compare NTLA with Peers
Further Reading
Research and guides that put NTLA’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.
More Healthcare Stock Analysis
In-depth reports on companies operating alongside NTLA — business models, bull and bear cases, and the metrics that matter.
Unlock the Full NTLA Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.